These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
60 related items for PubMed ID: 5608556
1. [Effect of the anticoagulant nafarin on the course of ischemic disease of the myocardium]. Semeniuk AV. Sov Med; 1967 Apr; 30(4):101-4. PubMed ID: 5608556 [No Abstract] [Full Text] [Related]
2. Potentiation of anticoagulant effect of warfarin by phenylbutazone. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. N Engl J Med; 1967 Mar 02; 276(9):496-501. PubMed ID: 6018280 [No Abstract] [Full Text] [Related]
3. [Effect of the anticoagulant nafarin on the immunological reactivity]. Kovalev IE, Lakin KM. Farmakol Toksikol; 1967 Mar 02; 30(6):696-9. PubMed ID: 5598440 [No Abstract] [Full Text] [Related]
4. [Interaction between anticoagulants and indomethacin]. Odegaard AE. Tidsskr Nor Laegeforen; 1974 Nov 30; 94(33):2313-4. PubMed ID: 4439389 [No Abstract] [Full Text] [Related]
5. Thrombolytic therapy in patients with an abnormality of blood coagulation. St John G, Talley JD. J Ark Med Soc; 1995 Jul 30; 92(2):81-2. PubMed ID: 7642479 [No Abstract] [Full Text] [Related]
6. Factor VII during warfarin treatment. Howarth DJ, Brozović M, Stirling Y, Reed M. Scand J Haematol; 1974 Jul 30; 12(5):346-54. PubMed ID: 4859330 [No Abstract] [Full Text] [Related]
7. [Case of polycythemia vera associated with myocardial infarction and cerebral thrombosis and treated by anticoagulant therapy]. Sawada K, Shmizu M, Konno T, Shibaki H, Sakurama S. Rinsho Ketsueki; 1983 Feb 30; 24(2):191-6. PubMed ID: 6655878 [No Abstract] [Full Text] [Related]
8. [Treatment of coronary insufficiency with nafarin]. Zhivoderov VM, Pin'kevich NM. Kardiologiia; 1966 Feb 30; 6(1):68-9. PubMed ID: 5970409 [No Abstract] [Full Text] [Related]
16. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators. Am Heart J; 2006 Nov 30; 152(5):967-73. PubMed ID: 17070169 [Abstract] [Full Text] [Related]
17. The contribution of plasma (R)- & (S)-warfarin and vitamin K concentrations to intra-individual variability in anticoagulation. Kamali F, Edwards C, Butler TJ, Wynne HA. Thromb Haemost; 2000 Feb 30; 83(2):349-50. PubMed ID: 10739399 [No Abstract] [Full Text] [Related]
18. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Brodin E, Seljeflot I, Arnesen H, Hurlen M, Appelbom H, Hansen JB. Thromb Res; 2009 Feb 30; 123(4):573-9. PubMed ID: 18474393 [Abstract] [Full Text] [Related]
19. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K. CMAJ; 1999 Sep 07; 161(5):493-7. PubMed ID: 10497604 [Abstract] [Full Text] [Related]
20. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hunninghake D, Kennedy JW, Applegate WB. Am Heart J; 2000 Oct 07; 140(4):631-6. PubMed ID: 11011338 [Abstract] [Full Text] [Related] Page: [Next] [New Search]